Nami Hirakawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nami Hirakawa has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Akihiko Suto
Department of Breast Surgery, National Cancer Center Hospital, Tokyo 104-0045, Japan
1 shared publication - Akiko Miyagi Maeshima
Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan
1 shared publication - Chikashi Watase
Breast Surgery Division, National Cancer Center Hospital, Tokyo, Japan
1 shared publication - Haruhi Maseki
Breast Surgery Division, National Cancer Center Hospital, Tokyo, Japan; Department of Surgery, Keio University School of Medicine, Tokyo, Japan
1 shared publication Kaishi Satomi
Diagnostic Pathology Division, National Cancer Center Hospital, Tokyo, Japan; Department of Pathology Medicine, Kyorin University School of Medicine, Japan
1 shared publication- Kenjiro Jimbo
Breast Surgery Division, National Cancer Center Hospital, Tokyo, Japan
1 shared publication
Latest Publications
- 13 May 2025
- Published by Springer Nature in Breast Cancer
- Vol. 32 (4) , 874-880
Reevaluating HER2-null breast cancer using an enhanced HER2 immunohistochemistry protocol
Human epidermal growth factor receptor 2 (HER2) status is crucial for the classification of breast cancer and the selection of its treatment. Although HER2-low breast cancer is a recognized therapeutic subgroup, the classification of HER2 immunohistochemistry (IHC) 0 remains unclear. We reassessed 58 HER2-null breast cancer cases using an enhanced HER2 IHC protocol and the VENTANA OptiView detection system. HER2 expression was evaluated based on membrane positivity rate (%) and staining intensity. Microscopic assessment was performed to determine the percentage of HER2-positive tumor cells. Digital image analysis was used to quantify staining intensity. Detectable membrane HER2 positivity was observed in all tumors previously classified as HER2-null; the positivity rates ranged from 0.33% to 90% and the staining intensity indicated both inter- and intratumoral heterogeneity. These findings suggest that enhanced HER2 IHC protocols can improve detection sensitivity. This approach may help to refine HER2 classification and optimize patient selection for HER2-targeted therapies. Further research is needed to determine the clinical significance of HER2 expression detected using enhanced protocols.
- 13 May 2025
- Published by Springer Nature in Breast Cancer
- Vol. 32 (4) , 874-880
Reevaluating HER2-null breast cancer using an enhanced HER2 immunohistochemistry protocol
Human epidermal growth factor receptor 2 (HER2) status is crucial for the classification of breast cancer and the selection of its treatment. Although HER2-low breast cancer is a recognized therapeutic subgroup, the classification of HER2 immunohistochemistry (IHC) 0 remains unclear. We reassessed 58 HER2-null breast cancer cases using an enhanced HER2 IHC protocol and the VENTANA OptiView detection system. HER2 expression was evaluated based on membrane positivity rate (%) and staining intensity. Microscopic assessment was performed to determine the percentage of HER2-positive tumor cells. Digital image analysis was used to quantify staining intensity. Detectable membrane HER2 positivity was observed in all tumors previously classified as HER2-null; the positivity rates ranged from 0.33% to 90% and the staining intensity indicated both inter- and intratumoral heterogeneity. These findings suggest that enhanced HER2 IHC protocols can improve detection sensitivity. This approach may help to refine HER2 classification and optimize patient selection for HER2-targeted therapies. Further research is needed to determine the clinical significance of HER2 expression detected using enhanced protocols.
- Open Access
- 1 February 2023
- Published by Elsevier in Asian Journal of Surgery
- Vol. 46 (9) , 3700-3704
Clinical significance of tumor cell seeding associated with needle biopsy in patients with breast cancer
- 1 February 2023
- Published by Elsevier in Asian Journal of Surgery
- Vol. 46 (9) , 3700-3704
Open AccessClinical significance of tumor cell seeding associated with needle biopsy in patients with breast cancer